01 Stock Market
The U.S. major indexes closed as follows: Dow Jones up 1.71% at 54,085.88; S&P 500 up 1.79% at 7,736.52; NASDAQ up 2.59% at 26,584.99. A broad risk-on mood, underpinned by easing geopolitical tensions and upbeat corporate earnings, helped all three gauges finish comfortably higher.
Semiconductors and AI plays topped the unusual-move board. Palantir Technologies (PLTR) jumped 29.45% to $162.66 after blockbuster results, while optical-network firm Applied Optoelectronics (AAOI) soared 19.44% to $131.63. Memory giant Micron Technology (MU) climbed 7.62% to $892.67; peers AMD (AMD) added 7.00% to $518.58 and NVIDIA (NVDA) rose 2.56% to $211.94, as data-center demand stayed hot. Legacy chipmaker Intel (INTC) advanced 10.84% to $100.86, and Marvell Technology (MRVL) gained 12.81% to $218.59. Outside chips, Apple (AAPL) firmed 1.96% to $309.38, and Tesla (TSLA) edged up 1.64% to $327.35, underscoring renewed strength across the tech complex.
Leveraged ETFs amplified the day’s moves. The bullish Direxion Daily Semiconductors 3× (SOXL) rallied 19.87% to $139.90, while its bearish counterpart SOXS fell 20.25% to $42.33. Broader tech exposure was in demand too, with Invesco QQQ (QQQ) up 3.40% at $723.85 and ProShares UltraPro QQQ (TQQQ) up 10.09% at $74.82, reflecting aggressive positioning for further gains.
02 Other Markets
U.S. 10-year Treasury yield was unchanged (0.00%), latest at 4.63%.
USD/CNH fell 0.06%, at 6.78; USD/HKD rose 0.0011%, at 7.84.
U.S. Dollar Index fell 0.02%, at 99.87.
WTI crude futures fell 0.50%, at 75.39 USD/bbl; COMEX gold futures fell 0.58%, at 4,128.60 USD/oz.
03 Top News
1. Palantir’s revenue nearly doubled, sparking a 30% share surge. The data-analytics firm also raised full-year guidance, citing “unleashed” demand for AI sovereignty solutions. CEO Alex Karp called the latest quarter’s performance “otherworldly,” reinforcing confidence in sustained growth.
2. Arista Networks delivered a 38% jump in quarterly sales on AI-driven networking demand. Adjusted EPS reached $1.02, beating estimates, and the company guided above consensus for the next quarter. Shares rallied about 13% in late trading, pushing the market cap past $250 billion.
3. AMD projected third-quarter revenue around $13 billion, topping forecasts, yet its stock slipped 9% on lofty expectations. Management highlighted accelerating orders for MI-series AI accelerators but warned of ongoing production constraints at key supplier TSMC. Investors appeared to seek an even stronger outlook after the stock’s year-to-date rally.
4. Booking Holdings reported a 7% rise in revenue to $7.35 billion amid resilient travel demand. Profit more than doubled to $1.95 billion, and the company reaffirmed full-year growth guidance despite Middle East conflict headwinds. Shares gained over 3% in extended trade.
5. Novo Nordisk lifted full-year guidance as appetite for weight-loss drug Wegovy remained robust. More than 5 million U.S. prescriptions for the oral version since January drove a 7% rise in quarterly sales. Management now sees adjusted sales falling no more than 6%, versus the prior outlook of up to 12%.
6. The Federal Trade Commission reached a landmark antitrust settlement with Caremark, a major pharmacy-benefit manager. Regulators said the agreement will lower out-of-pocket drug costs, boost price transparency and improve terms for community pharmacies. The move underscores the FTC’s intensified scrutiny of drug middlemen.
7. Amazon lost its bid to keep Perplexity’s AI shopping agents off its platform after a U.S. appeals court reversal. The Ninth Circuit ruled Amazon was unlikely to prove that Perplexity violated computer-hacking laws. The decision marks a precedent for how agentic AI tools may legally access e-commerce sites.
8. Amgen’s second-quarter revenue climbed 10% to $10.1 billion, prompting a higher full-year outlook. Strong demand for cholesterol drug Repatha and osteoporosis therapy Evenity fueled the beat. The biotech now expects 2026 earnings of $22.30–$23.50 per share, up from prior guidance.
9. Gilead Sciences posted an 8% rise in quarterly product sales, led by HIV treatments, despite a one-time acquisition charge. Revenue hit $7.8 billion, topping forecasts, and the company narrowed its full-year loss projection. Management highlighted robust growth in HIV prevention drug Yeztugo.
10. Wells Fargo outlined plans to launch tokenized deposits for corporate clients, signaling deeper forays into digital assets. The initiative aims to streamline settlement and cash-management processes using blockchain technology. The bank said it expects to roll out the service for commercial users later this year.
Sources: Reuters, Dow Jones Newswires, Public Market Data Disclaimer: This content is for reference only and does not constitute investment advice.
